Use of intravitreal triamcinolone and bevacizumab in Coats' disease with central macular edema.

[coats disease]

Intravitreal application of triamcinolone and bevacizumab in Coats ' disease with macular edema to improve visual outcome .Testing of best-corrected visual acuity (BCVA ), ophthalmoscopy , optical coherence tomography , fluorescein angiography , 30 Â° perimetry , and full-field electroretinography were performed at initial and follow-up visits . Medical treatment consisted of intravitreal injection of 1 .25 Â mg bevazicumab and 1 .25 Â mg triamcinolone , followed by intravitreal injections of 1 .25 Â mg bevazicumab at weeks 4 and 10 . Follow-up was 87 Â weeks .Perimetric results , including a temporal absolute scotoma and reduced electroretinographic amplitudes (photopic and scotopic conditions ), did not significantly change during the follow-up , but foveal retinal thickness decreased from 505 Â Î¼m to 212 Â Î¼m , and BCVA increased from 0 .3 at baseline to 1 .25 and remained stable during subsequent follow-up .Combined intravitreal treatment with bevacizumab and triamcinolone resulted in significant decrease of central retinal thickness and improved visual acuity in this case report . Severe local or systemic side-effects were not observed .

Diseases
Validation

Diseases presenting "edema" symptom

acute rheumatic fever

adrenomyeloneuropathy

aniridia

cadasil

canavan disease

classical phenylketonuria

coats disease

congenital toxoplasmosis

cushing syndrome

cutaneous mastocytosis

erythropoietic protoporphyria

esophageal carcinoma

fabry disease

familial mediterranean fever

focal myositis

harlequin ichthyosis

homocystinuria without methylmalonic aciduria

inclusion body myositis

lamellar ichthyosis

liposarcoma

lymphangioleiomyomatosis

malignant atrophic papulosis

pleomorphic liposarcoma

systemic capillary leak syndrome

trochlear dysplasia

von hippel-lindau disease

waldenstrÃ¶m macroglobulinemia

This symptom has already been validated